ibutamoren Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Ibutamoren is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels.   Wikipedia

Chemistry

  • SMILES: CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12
  • InChIKey: UMUPQWIGCOZEOY-JOCHJYFZSA-N
  • Mol. Mass: 528.68
  • ALogP: 1.77
  • ChEMBL Molecules:
    ibutamoren  
    ibutamoren mesylate  
More Chemistry

Pharmacology

Alternative names

ibutamoren | ibutamoren mesylate | l 163191 | l 163,191 | l-163191 | l-163,191 | mk0677 | mk 0677 | mk-0677 | mk-677

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Aging (Phase 1/Phase 2)

Alzheimer Disease (Phase 2)

Fibromyalgia (Phase 2)

Hip Fractures (Phase 2)

Kidney Diseases (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue